WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs),  today announced the signing of a Memorandum of Understanding (MOU) with AbTis, a leading ADC biotechnology company based in South Korea.

This partnership brings together AbTis' proprietary site-selective conjugation platform AbClick® and WuXi XDC's integrated discovery services and all-in-one development & manufacturing platform. The collaboration aims to accelerate ADC therapeutic innovation by integrating AbTis' cutting-edge technology into WuXi XDC's toolbox, while fostering new opportunities for global clients.

Through this agreement, WuXi XDC will incorporate AbTis' advanced site-selective conjugation technologies including the AbClick® Platform, which utilizes affinity peptide-assisted linkers to enable precise and efficient antibody-drug conjugation. Additionally, WuXi XDC will facilitate potential collaborations between AbTis and its extensive client network, expanding the global reach of AbTis Technologies while unlocking synergistic market opportunities.

This collaboration highlights a shared commitment to advancing innovation and delivering state-of-the-art solutions to the bioconjugate drug industry. By enhancing CMC platform capabilities, both companies aim to empower clients to accelerate preclinical candidate selection, develop next-generation ADCs, and expedite CMC development timelines.

Dr. Jimmy Li, CEO of WuXi XDC, commented, "This collaboration with AbTis underscores our commitment to advancing innovation through strategic partnerships and creating meaningful value for our clients. With the addition of AbTis' innovative conjugation technology into the WuXi XDC technology suite, it will provide our clients with broader options of advanced bioconjugation technologies and will tailormade solutions to support the advancement of next-generation ADCs and bioconjugate drugs."

Dr. Tae Dong Han, CEO of AbTis, commented, "This partnership with WuXi XDC marks a significant milestone for AbTis as we expand the reach of our site-selective conjugation technology. By leveraging WuXi XDC's extensive global network and integrated CRDMO platforms alongside AbTis' innovative bioconjugation technologies and comprehensive expertise, we aim to create a synergy that amplifies the accessibility and impact of our innovations. Together, we are well-positioned to drive and support the development of groundbreaking ADC therapeutics, delivering meaningful benefits to patients worldwide."